[Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens].
Prostate cancer (PCa) like other tumors expresses antigens that may serve as target for specific immunotherapy. Special antigen-presenting cells (e. g., dendritic cells) are capable of generating tumor-specific immunity. Cytotoxic T-cells (killer cells) are very effective against antigens and, consequently, against the respective tissue or tumor. Cancer testis antigens (CTA) are expressed in various human cancers but, aside from the testicles, not in normal tissue. Therefore, they are suitable for a specific tumor immunotherapy. We looked at different CTA (LAGE-1, PRAME, MAGE-C2, NY-ESO-1, SSX-2 and PAGE4) and their occurrence in prostatic cancer. Expression of CTA in various PCa cell lines and PCa material from patients was very heterogeneous. Only PAGE4 was expressed in primary PCa and in LnCaP cells as well as in hormone-dependent and hormone-refractory PCa probes. We conclude that PAGE4 should be further evaluated as a potential target for immunotherapy of PCa.
Prikler
L
L
Klinik für Urologie, CH-St. Gallen. ladislav.prikler@kssg.ch
Scandella
E
E
Men
Y
Y
Engeler
D S
DS
Diener
P-A
PA
Gillessen
S
S
Ludewig
B
B
Schmid
H-P
HP
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D000954:Antigens, Surface; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008297:Male; D008565:Membrane Proteins; D051379:Mice; D009363:Neoplasm Proteins; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy; D011471:Prostatic Neoplasms / Q000276:immunology / Q000628:therapy*; D012097:Repressor Proteins; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D013737:Testis / Q000276:immunology; D014407:Tumor Cells, Cultured
D000951:Antigens, Neoplasm; D000954:Antigens, Surface; C104948:CTAG1B protein, human; C510162:CTAG2 protein, human; D019496:Cancer Vaccines; C072012:MAGEB2 protein, human; C512965:Mageb2 protein, mouse; D008565:Membrane Proteins; D009363:Neoplasm Proteins; D012097:Repressor Proteins; C093962:synovial sarcoma X breakpoint proteins